{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:21:43Z","timestamp":1784409703556,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jdcr.2022.08.005","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T15:38:12Z","timestamp":1660145892000},"page":"24-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis"],"prefix":"10.1016","volume":"28","author":[{"given":"Annika","family":"Klumpp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Luessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinah","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Weidenthaler-Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Grabbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadrian","family":"Schepler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3-4","key":"10.1016\/j.jdcr.2022.08.005_bib1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000360528","article-title":"Multiple sclerosis: current knowledge and future outlook","volume":"72","author":"Kamm","year":"2014","journal-title":"Eur Neurol"},{"issue":"3","key":"10.1016\/j.jdcr.2022.08.005_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jdcr.2022.08.005_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/LGT.0000000000000661","article-title":"Vulvovaginal pyoderma gangrenosum in a patient treated with ocrelizumab for multiple sclerosis","volume":"26","author":"Breneman","year":"2022","journal-title":"J Low Genit Tract Dis"},{"issue":"3","key":"10.1016\/j.jdcr.2022.08.005_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/11595240-000000000-00000","article-title":"Etiology and management of pyoderma gangrenosum: a comprehensive review","volume":"13","author":"Ahronowitz","year":"2012","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jdcr.2022.08.005_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.jdcr.2022.08.005_bib6","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jdcr.2018.09.003","article-title":"A case of rituximab-induced pyoderma gangrenosum","volume":"4","author":"Georgakopoulos","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jdcr.2022.08.005_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/03009742.2016.1241298","article-title":"Life-threatening Rituximab-induced pyoderma gangrenosum successfully treated with intravenous immunoglobulin","volume":"46","author":"Vikse","year":"2017","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"10.1016\/j.jdcr.2022.08.005_bib8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamadermatol.2017.5980","article-title":"Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi Consensus of International Experts","volume":"154","author":"Maverakis","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2022.08.005_bib9","first-page":"34","article-title":"Treatment options for pyoderma gangrenosum","volume":"15","author":"Quist","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"10.1016\/j.jdcr.2022.08.005_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13221","article-title":"Pyoderma gangrenosum adverse event with rituximab use: a postmarketing pharmacovigilance analysis","volume":"33","author":"Aggarwal","year":"2020","journal-title":"Dermatol Ther"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622003538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622003538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:24:26Z","timestamp":1762475066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512622003538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":10,"alternative-id":["S2352512622003538"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.08.005","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}